Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy
- PMID: 12585833
- DOI: 10.7326/0003-4819-138-4-200302180-00014
Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy
Abstract
Fabry disease (alpha-galactosidase A deficiency) is an X-linked recessive lysosomal storage disorder. Although the disease presents in childhood and culminates in cardiac, cerebrovascular, and end-stage renal disease, diagnosis is often delayed or missed. This paper reviews the key signs and symptoms of Fabry disease and provides expert recommendations for diagnosis, follow-up, medical management, and the use of enzyme replacement therapy. Recommendations are based on reviews of the literature on Fabry disease, results of recent clinical trials, and expertise of the authors, all of whom have extensive clinical experience with Fabry disease and lysosomal storage disorders and represent subspecialties involved in treatment. All males and female carriers affected with Fabry disease should be followed closely, regardless of symptoms or treatment status. Clinical trials have shown that recombinant human alpha-galactosidase A replacement therapy--the only disease-specific therapy currently available for Fabry disease--is safe and can reverse substrate storage in the lysosome, the pathophysiologic basis of the disease. Enzyme replacement therapy in all males with Fabry disease (including those with end-stage renal disease) and female carriers with substantial disease manifestations should be initiated as early as possible. Additional experience is needed before more specific recommendations can be made on optimal dosing regimens for reversal; maintenance; and prevention of disease manifestations in affected males, symptomatic carrier females, children, and patients with compromised renal function.
Similar articles
-
[Management of Fabry disease].Orv Hetil. 2010 Aug 1;151(31):1243-51. doi: 10.1556/OH.2010.28796. Orv Hetil. 2010. PMID: 20656661 Review. Hungarian.
-
Fabry disease: a treatable lysosomal storage disorder.Natl Med J India. 2009 Jan-Feb;22(1):20-2. Natl Med J India. 2009. PMID: 19761154
-
Enzyme replacement therapy in Fabry disease: clinical implications.Curr Opin Nephrol Hypertens. 2003 Sep;12(5):491-5. doi: 10.1097/00041552-200309000-00002. Curr Opin Nephrol Hypertens. 2003. PMID: 12920395 Review.
-
Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Acta Neurol Scand. 2012 Aug;126(2):77-97. doi: 10.1111/j.1600-0404.2012.01661.x. Epub 2012 Mar 19. Acta Neurol Scand. 2012. PMID: 22428782 Review.
-
Fabry disease: focus on cardiac manifestations and molecular mechanisms.Herz. 2002 Nov;27(7):699-702. doi: 10.1007/s00059-002-2429-9. Herz. 2002. PMID: 12439642
Cited by
-
Fabry disease: raising awareness of the disease among physicians.Intern Emerg Med. 2012 Oct;7 Suppl 3:S227-31. doi: 10.1007/s11739-012-0821-x. Intern Emerg Med. 2012. PMID: 23073862 Review.
-
Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.BMJ Open. 2016 Apr 8;6(4):e010422. doi: 10.1136/bmjopen-2015-010422. BMJ Open. 2016. PMID: 27059467 Free PMC article.
-
α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.J Biol Chem. 2012 Aug 17;287(34):28386-97. doi: 10.1074/jbc.M112.351056. Epub 2012 Jul 6. J Biol Chem. 2012. PMID: 22773828 Free PMC article.
-
The Benefits of Family Screening in Rare Diseases: Genetic Testing Reveals 165 New Cases of Fabry Disease among At-Risk Family Members of 83 Index Patients.Genes (Basel). 2022 Sep 9;13(9):1619. doi: 10.3390/genes13091619. Genes (Basel). 2022. PMID: 36140787 Free PMC article.
-
Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.J Inherit Metab Dis. 2010 Oct;33(5):611-7. doi: 10.1007/s10545-010-9158-7. Epub 2010 Jul 6. J Inherit Metab Dis. 2010. PMID: 20607610
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical